🇺🇸 FDA
Patent

US 11001844

CRISPR/Cas-related methods and compositions for treating herpes simplex virus

granted A61PA61P27/02A61P31/22

Quick answer

US patent 11001844 (CRISPR/Cas-related methods and compositions for treating herpes simplex virus) held by Editas Medicine, Inc. expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Editas Medicine, Inc.
Grant date
Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P27/02, A61P31/22